Supinoxin provides encouraging tumor inhibition data
ROCKVILLE, Md.—The American Society for Clinical Oncology (ASCO) 2016 Genitourinary Cancers Symposium saw Rexahn Pharmaceuticals Inc. present new preclinical efficacy data for Supinoxin (RX-5902), its novel anticancer drug candidate. The compound is an orally administered, potential first- in-class, small-molecule inhibitor of phosphorylated-p68 (P-p68), which increases the activity of multiple cancer-related genes and plays a role in tumor progression and metastasis. Over-expression of P-p68 has been seen in solid tumors in melanoma, colon, ovarian and lung cancers. One study suggested Supinoxin achieved tumor growth inhibition of more than 60 percent in a xenograft model of renal cell cancer. Another xenograft study suggested it achieved dose-dependent tumor growth inhibition of more than 60 percent and a partial clinical response in 60 percent of the animals and a complete response in 10 percent of the animals at a dose of 70 mg/kg.